ArticleNature nanotechnology2026
A programmable DNA origami nanosyringe for directed membrane translocation.
Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bacterial contractile injection systems provide a model for membrane penetration and targeted delivery of molecular cargo through mechanical actuation. Replicating these features in synthetic nanoscale systems remains challenging, particularly with respect to coupling structural organization with dynamic actuation, reversibility and spatiotemporal regulation. Here we report a DNA origami nanosyringe that integrates these capabilities to enable programmable membrane translocation. The DNA origami nanosyringe comprises two ~70-nm DNA origami bundles crosslinked by a ~10-nm gold nanoparticle. One bundle forms a cholesterol-functionalized membrane-anchoring base, whereas the other serves as a DNA fuel-driven sliding needle. After binding to supported lipid bilayers or vesicle membranes, DNA-fuel actuation drives the needle downwards in ~14-nm steps, thereby enabling membrane penetration, while reverse actuation retracts the needle and promotes membrane resealing. We show that this device provides controllable delivery of cargo tethered to the needle tip into lipid-bounded compartments and can regulate biochemical processes within cell-sized environments, including membrane-localized hybridization chain reactions, RNA transcription and catalytic RNA cleavage. These results demonstrate a strategy for constructing dynamic DNA devices that operate at membrane interfaces and coordinate mechanical actuation with biochemical function.
Identifiers
42581195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.